nctId: NCT06381154 id: MC230404 id: NCI-2024-03078 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 23-009036 type: OTHER domain: Mayo Clinic Institutional Review Board id: MC230404 type: OTHER domain: Mayo Clinic id: P01CA084203 type: NIH link: https://reporter.nih.gov/quickSearch/P01CA084203 id: P30CA015083 type: NIH link: https://reporter.nih.gov/quickSearch/P30CA015083 briefTitle: Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-05 date: 2029-07-04 date: 2029-07-04 date: 2024-04-24 date: 2024-04-24 name: Mayo Clinic class: OTHER name: National Cancer Institute (NCI) briefSummary: This phase II trial tests how well photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy works in treating patients with pancreatic cancer that cannot be removed by surgery (unresectable), that has spread to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Photoradiation uses light activated drugs, such as verteporfin, that become active when exposed to light. These activated drugs may kill tumor cells. Vertoporfin may also increase tumor response to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy may kill more tumor cells in patients with unresectable, locally advanced or metastatic pancreatic cancer. conditions: Locally Advanced Pancreatic Adenocarcinoma conditions: Metastatic Pancreatic Adenocarcinoma conditions: Stage II Pancreatic Cancer AJCC v8 conditions: Stage III Pancreatic Cancer AJCC v8 conditions: Stage IV Pancreatic Cancer AJCC v8 conditions: Unresectable Pancreatic Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Biopsy name: Biospecimen Collection name: Computed Tomography name: Endoscopic Ultrasound name: Fluorouracil name: Irinotecan name: Leucovorin name: Lymph Node Biopsy name: Magnetic Resonance Imaging name: Oxaliplatin name: Pembrolizumab name: Photodynamic Therapy name: Positron Emission Tomography name: Questionnaire Administration name: Verteporfin measure: Overall response rate (ORR) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Incidence of adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Vinay Chandrasekhara, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False